Drug Watch

FDA Grants Orphan Drug Status to ITIL-168 for Melanoma
May 05, 2021

The FDA has granted an Orphan Drug designation to the investigational tumor-infiltrating lymphocyte therapy ITIL-168 for the treatment of patients with stage IIB to IV melanoma.

Voltaire-X Phase 3 Data for Chronic Plaque Psoriasis Support Interchangeability Application
April 26, 2021

Voltaire-X study data shows that switching several times between Cyltezo and Humira results in similar pharmacokinetics, efficacy, immunogenicity, and safety in people with moderate to severe chronic plaque psoriasis.

Otezla Phase 3 ADVANCE Trial Reports Improvement in Plaque Psoriasis Severity
April 25, 2021

Phase 3 trial of Otezla shows improved measures of disease severity in adults with mild to moderate plaque psoriasis regardless of their Body Surface Area affected by the disease.